This newsletter covers precious metals. Johnson & Johnson’s Rybrevant data has nothing to do with gold, silver, or copper, and we are not going to pretend otherwise.

But the PAPILLON results that headlined the World Conference on Lung Cancer in Seoul on September 13 are the kind of event that moves a mega-cap stock and ripples into portfolio conversations across asset classes. Precious metals investors hold diversified portfolios. Some of them hold JNJ. So here, briefly and honestly, is what the data actually says.

The Numbers

Patients treated with Rybrevant plus chemotherapy achieved a median overall survival of 34.3 months, compared with 27.9 months for chemotherapy alone. The combination extended median OS by 6.4 months despite 76 percent of eligible patients in the chemotherapy arm crossing over to second-line Rybrevant after disease progression. J&J and the IASLC described this as the longest reported median OS in this patient population.

For context, a commonly cited historical reference point is a 16.2-month real-world median overall survival reported in a cohort of patients with EGFR exon 20 insertion-mutated NSCLC. Going from about 16 months to 34 months is not incremental. That matters.

J&J presented the data at the Presidential Symposium at the IASLC 2026 World Conference on Lung Cancer. These overall survival findings build on the primary PAPILLON analysis, which showed progression-free survival of 11.4 months versus 6.7 months, corresponding to a hazard ratio of 0.40.

What Investors Should Weigh Carefully

The headline figure is real. The crossover design actually works against Rybrevant: when three-quarters of the control arm eventually received the drug anyway, any OS benefit becomes structurally harder to demonstrate. The fact that 6.4 months of separation survived that crossover is a meaningful signal about durable first-line advantage.

What investors should not overlook: the intention-to-treat hazard ratio came in at 0.87 with a 95% confidence interval of 0.66 to 1.14 and a p-value of 0.307. That is not statistically significant. The OS analysis was not a co-primary endpoint, and J&J is not claiming it was, but buyers of this result at face value need to hold that caveat alongside the impressive absolute number.

Additional data at WCLC 2026 covered continued work across Rybrevant and the subcutaneous formulation Rybrevant FASPRO, including supportive-care and prophylactic strategies in the COPERNICUS study and subcutaneous administration in the PALOMA program. The subcutaneous angle matters commercially. Reducing infusion burden is how a drug becomes the path of least resistance for oncologists choosing between otherwise comparable options.

The Competitive Backdrop

AstraZeneca is the reference competitor here. Its EGFR franchise, anchored by Tagrisso (osimertinib), dominates the broader EGFR-mutated lung cancer market, though it targets different mutation subtypes. In exon 20 insertions specifically, Rybrevant is now one of the most-validated options by survival data. That is a defensible commercial position, and J&J heads into the Deutsche Bank Healthcare Summit on Thursday, September 17, 2026 with fresh data behind it.

Bottom Line

For JNJ shareholders: the PAPILLON OS result strengthens Rybrevant’s market argument in a niche where the historical standard of care was genuinely poor. The non-significant hazard ratio limits how hard J&J can push OS as a regulatory talking point, but the magnitude of benefit in a crossover-heavy trial gives oncologists a credible first-line case. Watch how management frames the commercial trajectory at the Deutsche Bank summit. That framing, more than the p-value, will tell you where this asset sits in J&J’s near-term growth priorities.